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Abstract  
Background Cystic fibrosis (CF) is an inherited genetic disorder with high mortality and morbidity. 
CF is strongly correlated with malnutrition due to higher energy losses, pancreatic insufficiency, 
chronic inflammation, higher resting energy expenditure, and feeding problems. Malnutrition in CF 
patients associated with worse survival. Thus, appropriate and prompt nutritional intervention 
should be addressed to reduced malnutrition in CF patients. 
Methods The literature search was performed on 9 August 2021 in four major databases such as 
MEDLINE, EBSCOhost, Cochrane Reviews, and Web of Sciences to find the role of nutrition and 
pancreatic enzyme replacement therapy in pediatrics population with cystic fibrosis.  
Recent findings In recent decades, early nutritional management and pancreatic enzyme 
replacement therapy (PERT) have been shown to improve CF patient’s outcomes. Nutrition should 
be given in higher calories compared to healthy individuals with close and regular nutritional status 
monitoring. High protein and fat diets are essential for CF patient’s overall survival. Adequate level 
of micronutrients should be ensured to avoid morbidity caused by micronutrients deficiency. 
Regular pancreatic insufficiency screening should be done annually in order to start PERT early.  
Further research focusing on body composition, growth chart, protein intake, and PERT are needed 
to further improve the management of CF patient. 
Conclusion Nutritional intervention and PERT play an important role in prolonging CF patient 
survival. Both treatments should be initiated early with nutritional status close monitoring and 
tailored to each individual. Collaboration with parents and children is critical to warrant that CF 
patients followed the dietary advice. 
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Introduction 
 
Cystic fibrosis (CF), also known as mucoviscidosis, 
is one of the most common lethal inherited 
autosomal recessive genetic disorders found in the 
Caucasian population. There are approximately 1 in 
every 3,000 – 4,000 Caucasians born with this 
disorder. Although CF is notably found in 
Caucasians, it could also occur in other ethnicities 
with lesser prevalence.1  
Cystic fibrosis is caused by mutation in gene 
encoding the Cystic Fibrosis Transmembrane 
Conductance Regulator (CFTR) protein. Mutation 
leading to CFTR dysfunction mainly in regulating 
sodium and chloride transport system across 
numerous epithelial and other membrane cells. 
There are over one thousands of CFTR mutations of 
which give rise to its broad spectrum of phenotypes, 
ranging from single-organ pathology to classic CF.2 
CF can affect multiple organs such as liver, 
reproductive organs, intestine, and others, with 
considerable morbidity and mortality especially 
comes from its pathology in lungs and pancreas.1 
In the lungs, the chloride ion channel dysfunction 
results in decreased airway surface liquid, causing 
dehydration, thickened mucus, and ciliary function 
impairment. This condition promotes 
microorganisms to infect and causing inflammation, 
hence damaging and obstruct the airway. This 
vicious cycle of infection, inflammation, and airway 
obstruction contributes to the significant mortality in 
CF patients. In pancreas, the mechanism of chloride 
absorption and bicarbonate secretion of pancreatic 
ductal epithelial cells play essential roles in fluid 
secretion and optimizing digestive enzyme’s 
function. The CFTR mutation found in CF patients 
altered those mechanisms, causing pancreatic 
secretions to become lower in volume and pH with 
higher protein content, thus obstructing intra-
pancreatic ducts and impairing the absorption 
process. This premise is further supported by the fact 
that around 15-20% of CF babies have meconium 
ileus shortly after born. Malabsorption leading to 
undernutrition also expected due to the exocrine 
pancreas and intestinal resorptive processes 
malfunction, generating other morbidities for CF 
patients.3  
Numerous CF complications caused a lot of children 
did not surpass the first five years of life, with life 
expectancy approximately only six months when CF 
first introduced in 1938. Decades later, after the 
researcher's continuous effort to advance and 
develop CF therapies, there is a significant 
improvement in CF patients' survival with median 
survival age now beyond 30 years. One of the main 
pillar among other CF key treatment that could 
markedly increase patient’s survival is nutritional 
management.4    
Nutrition plays a vital role in CF prognosis; 
however, patient with CF usually presented with 
some degree of undernutrition due to malabsorption 
secondary to pancreatic insufficiency, higher energy 
intake, higher energy losses, and abnormal 
metabolic activity. Malnutrition in CF patients has 
been found to strongly correlated with poor 
pulmonary outcome, meanwhile good nutritional 
status is associated with prolonged survival and 
better lung function. Thus, close monitoring of 
nutritional status and early nutritional management 
is critical for CF patient’s overall survival. This 
review aims to summarize the latest evidence and 
guideline regarding the role of nutritional 
intervention along with the use of pancreatic enzyme 
replacement therapy in CF management, especially 




In order to summarize the role of nutritional 
intervention and pancreatic enzymes in CF, a 
database search has been performed using 
MEDLINE, EBSCOhost, Cochrane Reviews, and 
Web of Sciences on 9 August 2021. The search 
strategy was conducted by using keywords such as 
“pediatric”, “infant”, “children”, “nutrition 
therapy”, “diet therapy”, “pancreatic enzyme 
replacement therapy”, “PERT”, “cystic fibrosis”, 
and “mucoviscidosis”. The inclusion criteria were 
English language journal articles, guidelines, review 
articles, systematic review, or meta-analysis with 
pediatric as a subject population. The exclusion 
criteria were literatures that have been published for 
more than 5 years. Exceptional will be made for 
aged articles providing information that could not be 
found in recent articles. 
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Results and Discussion 
 
Nutritional status and cystic fibrosis 
 
Cystic fibrosis patients often presented with 
malnutrition. European Cystic Fibrosis Society 
(ECFS) Patient Registry data showed that in 2010 
about half of CF patients have some degree of 
malnutrition. The latest ECFS Patient Registry data 
showed that after the age of 2, children with CF have 
a lower average BMI compared with their non-CF 
same-age population.5 Several underlying 
mechanisms for malnutrition such as increased 
resting energy expenditure (REE), malabsorption 
caused by pancreatic insufficiency, deficiency of 
fat-soluble vitamins, chronic inflammation, CF-
related diabetes, decreased appetite (due to 
medications side effects), gastrointestinal problems 
(constipation, bacterial overgrowth, distal intestinal 
obstructive syndrome), and behavioral feeding 
problems. Malnutrition in CF leads to worse 
outcomes on account of worse lung function, 
immunological alteration, lower quality of life, 
stunted growth, and shorten life expectancy.6 The 
risk of malnutrition further worsen by CF-related 
diabetes and other metabolic complications. In CF-
related diabetes, patients have insulin deficiency that 
will lower insulin’s anabolic activity. Other CF 
complication, CF-related liver disease, correlated 
with several nutritional deficiencies, especially 
calcium, essential fatty acids, and fat-soluble 
vitamins.7  
For decades, effort has been made to decrease 
malnutrition in CF patients by using diet high in 
calorie and fat, fat-soluble vitamin supplementation, 
and pancreatic enzyme replacement therapy 
(PERT). Those efforts resulted in the improvement 
of CF patient’s nutritional status. The median BMI 
percentiles of children with CF in 2002 is 43% 
meanwhile, in 2017 the median increased to 75.1%. 
The same improvement could also be seen in the 
number of children with a weight < 10th of which the 
number decreased from 23.1% to 10.4%.8 
 
The role of nutritional management in cystic fibrosis 
patient 
 
Nutritional intervention should be started as early as 
possible by the time cystic fibrosis diagnosis is 
made, with the best outcome came from the 
detection in the first days of life through newborn 
screening.9 A good nutritional status is strongly 
associated with a better outcome, lower incidence of 
CF-related diabetes, fewer days of hospitalization, 
and better lung function. Better lung function has 
been proved by the capability of Forced Expiratory 
Volume in one second (FEV1) to reach its highest 
potential at six years of age in those children who 
reached the 50th percentile of weight for length/BMI 
earlier in life. After reached the higher FEV1, child 
with CF have been seen able to maintain good 
growth pattern for the rest of their early childhood.10  
Given the importance of nutritional status, 
nutritional care should be started aggressively early 
in life, preferably in the first year of life and 
continued over the lifetime. The European Society 
for Clinical Nutrition and Metabolism-The 
European Society for Pediatric Gastroenterology 
Hepatology-and The European Cystic Fibrosis 
Society (ESPEN-ESPGHAN-ECFS) through their 
guideline recommends that CF patients nutritional 
status should be monitored frequently by measuring 
anthropometric status (weight, height, BMI) and 
body composition.11 Body composition should also 
be measured due to the fact that around 14%-24% 
CF child with normal BMI has low fat-free mass 
(including muscle). Muscle composition correlated 
with better prognosis. Children with normal BMI do 
not necessarily have a better outcome if they have a 
low lean mass of muscle. One of the methods used 
in measuring body composition is using Bio-
Electrical Impedance Analysis (BIA) with CF-
specific equations, one of which was developed by 
Charatsi et al. BIA with CF-specific equations 
showed better accuracy in reflecting overall 
nutritional status than other examinations without 
validation to CF.12 However, there is also other 
recommended body composition assessment such as 
dual-energy X-ray absorptiometry (DXA), air 
displacement plethysmography, handgrip strength, 
and double-labeled water measurement. There was 
still limitation in the usage of body composition such 
as the unavailability of consensus on the used 
equation, technique, and proper references. Hence, 
there was no consensus in the threshold for fat free 
mass and fat free mass index, warranting further 
studies.13 
Besides muscle mass, bone mineral density 
(BMD) should also be assessed. Lean body mass and 
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bone mineral content are shown to better reveal 
nutritional deficits rather than low BMI and better 
predict lung function. Calella et al. found that lean 
body mass has significant correlation with FEV1 and 
was a significant predictor for pulmonary function.14 
Lower values of fat free mass and bone mineral 
density are associated with worse lung function. 
BMD is evaluated by using DXA due to high rate of 
osteopenia and osteoporosis in CF patients. The 
European Cystic Fibrosis Bone Mineralization 
Guidelines recommend that DXA examination be 
performed every 1-5 years, starting from 8 to 10 
years of age. For children with short height (the 
height is > one standard deviation lower than same-
age healthy children), bone mineral density Z score 
should be adjusted for their statural age to avoid 
overestimation in children with short stature.11  
The frequency of nutritional status measurement 
depends on the patient’s age and their nutritional 
status at the time of their presentation. Infants (0-2 
years old) with undernutrition should undergo 
nutritional status measurement every 1-2 weeks until 
they reached the 0 SD (50th percentile) weight and 
length for healthy same-age population. After they 
reached the intended nutritional status, they could 
continue monitoring monthly for their first year of 
life and every three months after. Ideally, every 
malnourished or stunted children should be 
monitored more frequently.11  
To ensure the success of nutritional intervention 
program, parents should be educated with this higher 
daily intake needs so they could provide the CF child 
with appropriate and balanced diets. Dietary 
counseling should also be given to the child to 
maintain healthy feeding and correct behavioral 
feeding problems commonly found in CF patient. A 
dietary review using 24-h recall or 3-5 days diet 
record will help in the qualitative and quantitative 
evaluation of nutritional intake. Thus, dietary review 
is recommended to be performed every 3 months 
especially for those with nutritional risk.11  
Special consideration should be taken in CF-
related diabetes (CFRD). CF patients with diabetes 
tend to have lower BMIs and height compared to 
those without diabetes. The nutritional decline 
commonly started 4 years before CFR diagnosis and 
was believed to be resulted from the catabolic effects 
of insulin insufficiency. In CFRD, good nutritional 
status should be achieved while maintaining the 
normal blood glucose levels. In general, patients 
with CFRD followed the same dietary 
recommendations with those without diabetes. 
However, there are several adjustments. In 
carbohydrate consumption, refined simple sugar 
particularly sugary beverages, juices and soda pop 
should be restricted. It is recommended to consume 
six servings of grains and 3-4 servings of dairy daily. 
In fats consumption, it is recommended to have food 
with higher omega-3 fatty acids content to lower 
inflammation which commonly seen in CFRD.16 
For newly diagnosed infants, the energy intake 
should come from exclusive breastfeeding if 
possible. If exclusive breastfeeding is not possible, 
regular infant formula can be used. Evidence 
showed that breastfed infants had better lung 
functions and fewer infections, possibly because of 
better immune function and docosahexaenoic acid 
(DHA) content in breastmilk. Children with poor 
growth or malabsorption might get benefit from high 
energy or hydrolyzed formula. However, there are 
no enough evidence to support the usage of those 
formulas. Both breastfed or formula-fed infants 
should take additional sodium supplementation and 
be introduced to solid food at the same time with 
healthy infants.11 The summary of energy and 
macronutrient recommendation can be seen in Table 
1.  
 
Recommendation for micronutrient intake 
 
CF patients often have micronutrient imbalance due 
to intestinal malabsorption, chronic inflammation, 
and increased sweating. Extra attention especially 
should be put on salt, iron, calcium, and zinc 
content. Salt supplementation is needed in all CF 
patients. Breastmilk, standard formula, and baby 
foods have relatively low sodium content and do not 
provide adequate sodium. Sodium deficiency could 
impair infant growth; thus, sodium assessment and 
supplementation should be carried out in infants. 
The ESPEN-ESPGHAN-ECFS guideline 
recommends that breastfed infants are given 1-2 
mmol/kgbodyweight/day sodium diluted in formula 
or water whenever sodium deficiency is discovered. 
However, this dosage can be increased by 
considering the presence of hot environmental 
conditions, diarrhea, vomiting, or other conditions 
that could make significant sodium losses. The 
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North American guidelines recommend that sodium 
supplementation in infants does not exceed 4 
mmol/kg body weight/day. In older children, the 
body's sodium level could be assessed through 
sodium: creatinine ratio. Supplementation could be 
given by sodium chloride capsules administered 
several times a day.11  
Malabsorption in CF patients leads to low level 
of fat-soluble vitamins, including vitamin D. Low 
level of vitamin D resulted in low calcium. Calcium 
level in CF patients should be assessed at least 
annually with special consideration in children with 
growth faltering or weight stagnation. Calcium 
supplementation should be given if calcium intake is 
deficient, according to the daily recommended 
calcium intake established by the European Food 
Safety Authority (EFSA) that is shown in the 
summary table below (Table 2).11  
Malabsorption also leads to iron deficiency in CF 
patients, resulted in iron deficiency anemia and poor 
outcome. Iron levels should be monitored annually. 
The ESPEN-ESPGHAN-ECFS guidelines 
recommend that iron deficiency be screened first 
through serum iron values. If the result is low, 
further laboratory work such as serum ferritin, 
transferrin saturation, and total iron-binding 
capacity should be done to differentiate between 
iron deficiency anemia or anemia of chronic 
inflammation. Iron supplementation could be given 
if the iron deficiency is proved.11  
Zinc deficiency was correlated with growth 
faltering, eye problems, delayed sexual maturation, 
and anorexia in CF patients. Thus, zinc 
supplementation is recommended in CF child with 
aforementioned condition with the supplementation 
dosage 1 mg/kg/day (max 15 mg/day) in infants (0-
2 years) and 15mg/day in older children (2-18 
years). The supplementation is suggested to be given 
in 6 months. 
CF children are commonly found with fat-soluble 
vitamin (vitamin A, D, E, K) deficiency with a 
prevalence 10-35%, resulted from pancreatic 
insufficiency. Low levels of vitamin A correlated 
with impaired lung function and poorer clinical 
status in CF patient. Low levels of vitamin D 
associated with reduced bone mineral density. Low 
levels of vitamin E resulted in the increase of 
oxidative damage and low level of vitamin K leads 
to increase susceptibility of significant bleeding and 
low bone mineral density. Numerous morbidities 
associated with fat-soluble vitamin give a rationale 
for fat-soluble vitamin plasma level evaluation 
annually. If there is a deficiency, supplementation 
should be given. It is better to consume the vitamins 
simultaneously with high-fat diets and pancreatic 
enzyme supplementation to increase absorption.11  
Vitamin A level in serum should reach the normal 
range of serum retinol concentration. 
Supplementation can be started by giving low-dose 
retinol and gradually stepping up the dosage guided 
by the evaluation of serum values. Alternatively, in 
children age 6-8 years, supplementation can also be 
given in the form of daily provitamin beta carotene, 
with the dosage 1 mg/kg body weight/ day for 2 
weeks and with 10mg/day as maintenance dose 
thereafter. If the normal values have been achieved, 
the frequency of retinol serum level concentration 
could be lowered to once in a year. The sign of 
vitamin A toxicity should also be evaluated 
regularly.17  
For vitamin D, there is a variety of recommended 
plasma levels between studies. The US Cystic 
Fibrosis Foundation recommends the minimal 
threshold for 25-hydroxy vitamin D (25(OH)D) 
concentration in serum is 30ng/mL, meanwhile The 
European Cystic Fibrosis Bone Mineralization and 
the ESPEN-ESPGHAN-ECFS guidelines 
recommends the minimum value is 20ng/mL. The 
supplemental dose of vitamin D is still being 
debated; however, it is recommended to give 400 
IU/day with maximum dose 1000IU/day in infants, 
and 800 IU.day with maximum dose 2000 IU and 
4000 IU/day for children 1-10 years and >10 years, 
respectively. Vitamin D dosage should also be 
determined based on the initial serum concentration, 
sun exposure degree, and dietary intake. Similarly 
with vitamin A, vitamin D serum levels should also 
be monitored annually.11 
Regular vitamin E (α-tocopherol) 
supplementation in CF patients is also 
recommended especially for patient with serum α-
tocopherol:cholesterol ratio less than 5.4 mg/g. The 
vitamin E supplement should be given in order to 
achieve the recommended serum α-tocopherol 
concentration for CF patient. Lastly, another fat-
soluble vitamin that should be given to CF patient is 
Vitamin K1. Until now, there is no consensus in the 
most effective dosing for vitamin K1. However, it is 
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believed that the best supplementation dosage are 
0.3-1mg/day for infants and 1-10mg/day for older 
children and adults.11 
 
The goal for nutritional status 
 
The main goal for CF patient is to reach the same 
growth with their healthy same-age population when 
at the same time also have a high lean body (muscle) 
mass. Indicators that are used for defining adequate 
nutritional status differs from age to age. In infants 
(0-2 years), the nutritional status is said to be 
sufficient when patient weight for length (WFL) 
reached ≥ 50th percentile of their age-matched 
healthy population. Meanwhile in older children (2-
18 years), the indicator is ≥ 50th percentile of BMI. 
Ideally, growth chart adapted from patient own 
ethnicity or nationality will be better to evaluate the 
nutritional status. If there are no adapted growth 
chart version, international growth chart (GC) 2006 
by World Health Organization (WHO) and Centers 
for Disease Control and Prevention (CDC) 2000. 
Originally, WHO 2006 GC is commonly used in 
infant aged 0-2 years meanwhile CDC 2000 in older 
children aged 2-18 years. However, in the CF 
population, there were discrepancy between those 
two GCs in certain ages. Zhang et al. reported that 
29% children aged 2 years with WFL ≥ 50th 
percentile on WHO GC were < 50th percentile on 
CDC GC. Besides, in BMI GC, 50th percentile on 
CDC GC was equal with 70th percentile and 67th 
percentile on WHO GC. This discrepancy resulted 
on inaccurate nutritional target and clinical 
outcomes prediction. Machogu et al. in his study 
found that patients with WFL ≥ 50th percentile on 
both charts had a significant higher FEV1 compared 
to WFL ≥ 50th percentile on single chart alone. This 
finding resulted in the release of Cystic Fibrosis 
Foundation guideline with WFL target ≥ 75th 
percentile on WHO GC for children aged 12-24 
months. Further studies comparing long term 
outcomes in CF patients using WHO, CDC, or 
national GC are needed.13 
CF children that already reached their desired 
nutritional status can be given preventive nutritional 
counseling in order to maintain their good nutrition. 
If the children experienced weight stagnation, 
weight faltering, or failure to thrive, diet 
modification and oral nutritional supplementation 
should be given to promote adequate growth. For 
children with persistent undernutrition, another 
measure such as enteral tube feeding, should be 
considered.  
Anthropometric measurement using BMI alone 
in older children is not enough to define adequate 
nutritional status. Body composition measurement 
should also be done to ensure that lean body 
(muscle) mass contributed for a significant portion 
in those measurement. High BMI with low lean 
body mass and high fat composition in the exact 
opposite, contributed for poor outcome.15 
Additionally, annual blood tests for nutritional 
review; such as iron status, blood count, electrolyte, 
plasma fat-soluble vitamin levels, serum liver 
function test; should also be performed to further 
evaluate CF patient nutritional status.11 Table 3 
summarizes the goal of nutritional status in CF 
patients. 
 
The role of pancreatic enzyme replacement therapy in 
cystic fibrosis patient 
 
Pancreatic insufficiency is found in 85-90% of CF 
patients and strongly correlated with malnutrition. It 
is commonly developed in the first year of life. The 
CFTR mutation impaired the chloride and 
bicarbonate transport system in pancreatic epithelial 
causing pancreatic secretions became thickened 
with decreased pH, leading to pancreatic ductal 
obstruction. Pancreatic chronic obstruction resulted 
in the impairment of pancreatic exocrine enzyme 
digestive function and created fibrosis leading to 
pancreatic insufficiency. CF patient with pancreatic 
insufficiency could not digest and absorb fat diet or 
fat-soluble vitamin due to the dysfunction of 
exocrine pancreatic enzyme, hence, the infants with 
pancreatic insufficiency commonly have lower 
weight and length z-score compared to their healthy 
counterparts. The children passed 80% of their diet 
fat contents in their stool due to lipase deficiency.18 
The pancreatic insufficiency should always be 
screened in every CF patient by the time of diagnosis 
and should be repeated annually. CF patient should 
also be questioned about gastrointestinal symptoms 
during clinical follow-up. Pancreatic insufficiency 
ought to be suspected if patient clinically has 
diarrhea without any other possibility or known to 
have 2 CFTR mutation that associated with 
pancreatic insufficiency.11 Several methods to 
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diagnose pancreatic insufficiency such as fecal 
pancreatic elastase-1 examination and coefficient of 
fat absorption. If the results are abnormal, the PERT 
should be initiated as early as possible. The 
abnormal results defined by low fecal pancreatic 
elastase-1 (<100µg/g stool).18 
Nowadays, PERT has becoming one of the main 
treatment for CF patients due to its ability in 
improving life expectancy and nutritional status of 
CF patients (Table 4).19 ECFS Registry Data 
collected from 38 countries showed that in 2018, 
approximately 83% patient with CF has already used 
PERT.5 The dosage for PERT determined by the 
lipid content in patient diet and the lipase needed for 
the diet. For infants up to 12 months, it is 
recommended to give 2000-4000 U lipase/120mL 
breastmilk or formula and 2000 U lipase/gram of fat 
in diet if infants already consume solids. For 
children 1-4 years, it is recommended to take 2000-
4000 U lipase/gram dietary fat with maximum 
dosage 10.000/U lipase/kg per day. In children > 4 
years, it is suggested to take PERT with starting dose 
500 U lipase/kg/meal with maximal dosage 10.000 
U/lipase/kg per day. PERT usually given in the form 
of enteric-coated tablets or microsphere.11 However 
the dosing of PERT was still much debated. The 
usage of lipase units/kg body weight/meal as a 
denominator only used body weight to decide PERT 
dosage and could result in over or under 
supplementation based on the nutrient intake. 
Meanwhile, the usage of lipase units/g fat does not 
implicate other macronutrients.13 Besides, there was 
no correlation found between PERT dose and BMI. 
Gelfond et al in his studies found that the higher 
PERT dosing do not give a better clinical benefit 
compared to lower dosing regimen.20  
 
Other important assessment in cystic fibrosis children 
 
CF correlated with numerous complications. Other 
examinations are performed in order to detect those 
complications in early stage. The measurement of 
pulmonary function by using forced expiratory 
volume in 1s (FEV1) should be performed every 3 
months to detect the decline of lung function. FEV1 
can also be used to evaluate the improvement after 
nutritional intervention. CF also could lead to liver 
disease; thus, the liver function should also be 
monitored annually by physical examination, 
enzyme assays, and ultrasound. Liver disease should 
be suspected if CF patient presented with 
hepatomegaly, persistent abnormal liver function 
test (3 months consecutive above upper normal 
limits aspartate transaminase, alanine transaminase, 
and gamma-glutamyl transpeptidase), and abnormal 
ultrasonography. The blood glucose test is suggested 
to be conducted annually in order to detect CF-




Nutritional intervention and PERT play an essential 
role in CF management and contribute to better 
survival. Given its importance, nutritional 
intervention and PERT should be initiated as early 
as possible by the time the CF diagnosis is made. 
The nutritional intervention consists of giving a 
higher daily energy intake than healthy individuals 
(with special consideration to higher protein and fat 
diet composition), micronutrient supplementation, 
and fat-soluble vitamins supplementation. The 
nutritional status should be monitored regularly by 
measuring the anthropometric status. In addition, 
other assessments that could also reflect nutritional 
status should also be performed regularly, such as 
body composition, bone mineral density, numerous 
serum biomarkers, and electrolyte concentration. 
Collaboration with parents and children also 
important. Parents and children should be educated 
on the importance of following dietary nutrition 
advice and regularly checking their condition. 
Besides nutritional intervention, PERT should be 
initiated early when pancreatic insufficiency is 
suspected in follow-up visit. Early administration of 
PERT correlated with better outcomes.  
Even though a comprehensive guideline in 
managing CF patient nutrition was already 
available, there are some potential fields to be 
explored in order to further improving holistic CF 
management. Research aims to determine the 
consensus in body composition measurement (in 
regard to its technique, equation, fat free mass and 
fat free mass index threshold) and growth chart; 
further investigation in recommended protein intake 
and protein sources that could easily digested by CF 
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Table 1. The summary of energy and macronutrient recommendation in CF patient11,16 
 
Topic Age Recommendation 
Recommended Daily 
Energy Intake 
All ages 110-200% calories of their recommended dietary allowance for similar-
age healthy population 
Dietary Composition All ages 35%-40% fat, 40-45% from carbohydrates, and 20% protein 
Education Infants and 
younger child 
Parents should be educated about child’s higher daily energy intake needs 
so they could provide the CF child with appropriate and balanced 
composition of diets 
 Older child Dietary counseling should be given to maintain healthy feeding and 
correct behavioral feeding problems 
Dietary Review All ages Dietary review should be assessed every 3 months by using 24-h recall or 
3-5 day diet record in order to evaluate qualitative and quantitative 
nutritional intake and whether patient/parents have already adhered to 
nutritional advices. 
CFRD All ages Carbohydrate: limit refined simple sugar, six servings of grains, and 3-4 
servings of dairy 
Fats: consume food with higher omega-3 fatty acids content 
Breastfeeding Infants (0-2 
years) 
Exclusive feeding if possible, formula feeding if not possible, with 
additional sodium supplementation. Solid foods should be started at the 
same age with healthy population. 
 
Table 2. The summary of micronutrient recommendation in CF patient11 
 
Micronutrient Age Evaluation Recommendation 
Sodium Infants (0-2 years) Sodium:creatinine 
ratio 
1-2 mmol/kg body weight/day sodium diluted in 
formula or water. Can be increased up to 4 
mmol/kg body weight/day (in the present of hot 
environmental conditions, diarrhea, vomiting) 
Older children Sodium chloride capsules administered several 
times a day 
Calcium 0-6 months Calcium intake should 
be assessed annually. 
More frequent 
assessment can be 
performed if there is a 
growth faltering 
200 mg daily 
7-11 months 280 mg daily 
1-3 years 450 mg daily 
4-10 years 800 mg daily 
11-17 years 1150 mg daily 
18-25 years 1000 mg daily 
Iron All ages Annually using serum 




and total iron binding 
capacity test. 
Give iron supplementation only after resolving 
other possible etiology (example: inflammation) 
and the iron deficiency still persists 
Zinc Infants (0-2 years) 
with zinc deficiency 
risk 
Identify infants or 
child with zinc 
deficiency risk: growth 
faltering, eye 
problems, delayed 
sexual maturation, and 
anorexia 
 
1mg/kg/ day (maximum 15 mg/day) for 6 months 
Child > 2 years with 
zinc deficiency risk 
15 mg/day for 6 months 
Fat-Soluble Vitamins 
Vitamin A All ages Annually, and 3-6 
months after the 
change in dosage. 
Vitamin A supplementation should be given if 
patient do not reach their normal range of serum 
retinol concentration. The supplementation that 
could be given: 
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Evaluate sign of 
toxicity 
• Retinol (low-dose, gradually increase the 
dosage guided by the retinol serum values) 
children age 6-8 years Alternative to retinol, daily provitamin beta 
carotene 1 mg/kg body weight/ day for 2 weeks and 
10mg/day as maintenance dose thereafter 
Vitamin D Infants  Annually, and 3-6 
months after the 
change in dosage. The 
minimum target is 
serum-25 (OH) D 
20ngmL 
400 IU/day (maximum 1000 IU/day) 
Children 1-10 years 800 IU/day (maximum 2000 IU/day) 
Children > 10years 800 IU/day (maximum 4000 IU/day) 
Vitamin E Infants (< 12 months) Annually, and 3-6 
months after the 
change in dosage. The 
target is serum α-
tocopherol :cholesterol 
ratio > 5.4 mg/g 
50 IU/day 
> 1 years 100-400 IU/day 
Vitamin K Infants   0.3-1 mg/day 
Older children 1-10mg/day 
 
Table 3. The nutritional status goal in CF patient11 
 
Age Measurement Target Evaluation 
Infants (0-2 years) Weight-and-length ≥ 50th percentile of their age-
matched healthy population 
• Every 1-2 weeks if the 
weight-and-length/BMI 
do not reach 50th 
percentile 
• Every 1 months in the 
first year of life 
• Every 3 months > 1 
years of life 
Older children (2-18 
years) 
BMI ≥ 50th percentile of their age-
matched healthy population 
Other Assessment 
Children 8-10 years Bone mineral density 
(BMD) 
Matched with standard BMD z 
score of same age and sex 
healthy individuals 
Every 1-5 years depends on 
the presence of risk factors 
using DXA 
All age Body composition High lean body muscle mass  Evaluation using BIA with 
CF-specific equations, DXA, 
air displacement 
plethysmography, hand grip 
strength, and double labelled 
water measurement 
 
Table 4. The recommended PERT dosages11 
 
Age Dosage 
Infants (0-12 months) 2000-4000 U lipase/120mL breastmilk or formula and 2000 U lipase/gram of fat in diet if 
infants already consume solids 
Child (1-4 years) 2000-4000 U lipase/gram dietary fat with maximum dosage 10.000/ u lipase/kg per day 
Child (> 4 years) starting dose 500 U lipase/kg/meal with maximal dosage  
• 10.000 U/lipase/kg per day, or 
• 1000-2500 U lipase/kg per meal, or 
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